$286.37 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter

Brokerages expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to announce $286.37 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Integra LifeSciences Holdings Corporation’s earnings, with the highest sales estimate coming in at $288.80 million and the lowest estimate coming in at $284.00 million. Integra LifeSciences Holdings Corporation posted sales of $250.33 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 14.4%. The firm is expected to announce its next earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $286.37 million for the current financial year, with estimates ranging from $1.12 billion to $1.20 billion. For the next year, analysts expect that the company will post sales of $1.29 billion per share, with estimates ranging from $1.19 billion to $1.55 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. The company had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the business posted $0.40 earnings per share.

A number of brokerages have recently weighed in on IART. UBS AG reaffirmed a “buy” rating and set a $60.00 price target (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Oppenheimer Holdings, Inc. set a $60.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a report on Saturday, June 24th. Cantor Fitzgerald began coverage on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, June 29th. They set an “overweight” rating and a $65.00 price target for the company. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $53.00 price target (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Integra LifeSciences Holdings Corporation currently has an average rating of “Buy” and a consensus target price of $53.54.

COPYRIGHT VIOLATION NOTICE: “$286.37 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/09/19/286-37-million-in-sales-expected-for-integra-lifesciences-holdings-corporation-iart-this-quarter.html.

Integra LifeSciences Holdings Corporation (IART) traded down 3.53% during mid-day trading on Friday, hitting $50.05. 765,566 shares of the stock traded hands. The firm’s 50-day moving average price is $50.51 and its 200-day moving average price is $48.58. The firm has a market cap of $3.91 billion, a P/E ratio of 61.04 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42.

In related news, Director Donald E. Morel, Jr. acquired 10,000 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was acquired at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the transaction, the director now directly owns 29,612 shares in the company, valued at $1,458,391. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Donald E. Morel, Jr. acquired 2,500 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average price of $49.29 per share, with a total value of $123,225.00. Following the completion of the transaction, the director now owns 29,612 shares in the company, valued at $1,459,575.48. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 17,550 shares of company stock valued at $864,842. 21.50% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC increased its position in Integra LifeSciences Holdings Corporation by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after purchasing an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC increased its position in Integra LifeSciences Holdings Corporation by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after purchasing an additional 799 shares in the last quarter. LS Investment Advisors LLC increased its position in Integra LifeSciences Holdings Corporation by 90.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock worth $102,000 after purchasing an additional 1,147 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Integra LifeSciences Holdings Corporation by 223.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock worth $107,000 after purchasing an additional 1,751 shares in the last quarter. Finally, Turner Investments LLC acquired a new position in Integra LifeSciences Holdings Corporation during the 1st quarter worth approximately $126,000. Institutional investors and hedge funds own 84.90% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply